$PRLD

Prelude Therapeutics Inc

Prelude Therapeutics is a precision oncology company that discovers and develops cancer medicines for patients with underserved cancers and high unmet medical need. Its pipeline includes kinase inhibitors, targeted protein degraders and precision antibody-drug conjugates. The company’s programs include a mutant-selective JAK2V617F inhibitor, a KAT6A degrader, mutated calreticulin degrader antibody conjugates and other degrader payloads for antibody-drug conjugates. Prelude also works with AbCellera on discovery and development of degrader antibody conjugates. Prelude develops drug candidates and advances them into clinical trials, and collaborates with partners on selected programs. Under licensing agreements, it may receive upfront payments, milestones and royalties; its AbCellera collaboration also provides for joint programs and licenses of degrader payloads. It relies on third parties to manufacture, store and distribute its product candidates. Prelude is headquartered in Wilmington, Delaware.

0
2
4

No SEC Form 4 filings for $PRLD in the last 30 days.

See all $PRLD insider activity →
Med

Prelude Therapeutics reports Q3 results

Prelude Therapeutics (PRLD) reported Q3 GAAP EPS loss of $0.12, revenue of $5.6M (down 13% Y/Y), and net loss of $12.5M (down 36% Y/Y). R&D expenses fell 32% to $14.8M, while G&A expenses decreased 2% to $5.1M. The company had $142.7M in cash and equivalents, with a runway into Q2 2028.

Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Prelude Therapeutics Inc (PRLD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Enrollment of Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer is underway; initial proof of concept data anticipated

PRLD sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 6 news stories mentioning PRLD (Prelude Therapeutics Inc). Coverage has skewed bearish: 0 bullish, 2 neutral, and 4 bearish.

Recent PRLD coverage spans earnings, financial news and regulation.

What's driving PRLD

AlphAI scores every news story that mentions PRLD with an AI model for sentiment and relevance, and aggregates insider trades from Prelude Therapeutics Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $PRLD

Score

Prelude Therapeutics reports Q3 results

Prelude Therapeutics (PRLD) reported Q3 GAAP EPS loss of $0.12, revenue of $5.6M (down 13% Y/Y), and net loss of $12.5M (down 36% Y/Y). R&D expenses fell 32% to $14.8M, while G&A expenses decreased 2% to $5.1M. The company had $142.7M in cash and equivalents, with a runway into Q2 2028.

$PRLDMedEarnings

Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Prelude Therapeutics Inc (PRLD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Enrollment of Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer is underway; initial proof of concept data anticipated

Here are Thursday's biggest analyst calls: Apple, Nvidia, Tesla, Alphabet, Kraft Heinz, Lyft, Palo Alto & more

Analysts made several calls on Thursday. Goldman upgraded Sunbelt citing growth improvement. Wolfe reiterated Tesla as peer perform. Bernstein downgraded Palo Alto Networks, Okta, and SentinelOne due to valuation. Citizens upgraded JBHT to market outperform. Daiwa reiterated Nvidia as outperform but lowered its price target to $245. RBC initiated Kraft Heinz as outperform. Wells Fargo initiated several bitcoin miners as overweight. Barclays reinstated Paramount Skydance as underweight and Warner

$PRLDMedAI 9/10Clinical / regulatory

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

Prelude Therapeutics Inc (PRLD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader Phase 1 study of PRT13722 in patients with HR+ breast cancer anticipated to begin enrolling patients in the fourth

Biotech Stocks At 52-Week Highs - ELOX, PRLD, ARGX, BOLD, CORT

Several biotech stocks hit 52-week highs on August 21, 2026. Eloxx (ELOX) rose 16% to $23.40, reporting a Q2 net loss of $4.5M. argenX (ARGX) reached $1,058.69, with positive trial results for VYVGART. Corcept (CORT) hit $123.44, reporting $256M in Q2 revenue. Boundless Bio (BOLD) reached $3.02, initiating a first-in-human trial. Prelude (PRLD) peaked at $6.38, advancing JAK2V617F in Phase 1 trials.

Top Biotech Gainers: DERM Advances On Emrosi Growth, IOVA Revenue Climbs 66%, CAI Raises Guidance

Journey Medical (DERM) rose 13% on strong Q2 results, with revenue up 23% to $18.5M. Iovance (IOVA) gained 11% on 66% revenue growth to $99.3M. Caris (CAI) advanced 8% after raising 2026 revenue guidance to $1.03B-$1.04B. Prelude (PRLD) up 8% on narrower Q2 loss. Compugen (CGEN) gained 7% on COM701 trial progress. Conexeu (CNXU) rose 4% on regenerative aesthetics market opportunity.

Related tickers